Oric PharmaceuticalsORIC
About: ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Employees: 115
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
6,175% more call options, than puts
Call options by funds: $3.26M | Put options by funds: $52K
96% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 26
35% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 20
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
8.42% more ownership
Funds ownership: 98.98% [Q3] → 107.4% (+8.42%) [Q4]
6% more funds holding
Funds holding: 122 [Q3] → 129 (+7) [Q4]
14% less capital invested
Capital invested by funds: $715M [Q3] → $612M (-$103M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
JP Morgan Anupam Rama 22% 1-year accuracy 13 / 60 met price target | 285%upside $22 | Overweight Maintained | 26 Feb 2025 |
HC Wainwright & Co. Robert Burns 27% 1-year accuracy 46 / 173 met price target | 268%upside $21 | Buy Reiterated | 26 Feb 2025 |
Financial journalist opinion
Based on 3 articles about ORIC published over the past 30 days









